Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI and Cetuximab in EGFR Wild Type Locally Advanced Rectal Cancer
NCT03391843Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in rectal cancer, sponsored by Renji Hospital. Started Dec 2017; status: active, not recruiting.
02
Drugs
cetuximab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03391843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391843.